The pandemic has contributed to the rise in deaths from cardiovascular diseases. In the first half of 2020, almost 40 thousand people died from acute coronary syndrome, and more than 220 thousand people died from coronary heart disease. For many years, cardiovascular disease has been at the top of the mortality statistics rating. Pilot drug reimbursement projects are intended to reduce this high rate; their start was scheduled for July 2020. However, COVID-19 has made its own adjustments.
Initially, the expert community was presented with three models of drug provision for the population: the first provides for 100% provision of patients with the most inexpensive drugs on a free basis, the second implies free provision of drugs to patients at a median price, which includes almost all manufacturers declared under the program for cardiovascular disease; the third is co-financing, when the state pays the patient a part of the price of a prescription drug, such a pilot project is already being implemented in the Kirov region at the expense of the regional budget.
Last fall, it became known that 47 regions expressed a desire to participate in the pilot project, 23 drugs were identified. The regulatory framework is currently being finalized. Perhaps, after a detailed analysis, taking into account all risks, the program will start working next year.
Today, Russian citizens can count on free medicines only when they are in the hospital — the costs of purchasing medicines are covered by the compulsory medical insurance system. People with disabilities, veterans, and children under three years of age receive outpatient medicines at a low cost — this is about 20% of the total population. It is assumed that in the future, the drug insurance system will make available drug care for all working or non-working citizens of the country.
The issues of the availability of medicines are key for the government, the scientific community and business. At the conference "State regulation and the pharmaceutical industry: continuation of the dialogue" the expert community will pay special attention to them. Proposals for the rational and effective use of drugs will be formulated and sent to the regulator.
On October 27, 2020, the main sectoral scientific and practical conference "Government regulation and the Russian pharmaceutical industry 2020: continuation of the dialogue" will be held online. The program: issues of the availability of medicines and the choice of optimal mechanisms for the implementation of the drug reimbursement system, the availability of drug insurance, quality control in the field of drug circulation: reality and prospects. Implementation of legislative initiatives: interchangeability, regulatory guillotine, labeling. The focus is on global challenges and benchmarks for the development of the pharmaceutical industry. Investment attractiveness, export potential. Instruments to support the development of the Russian pharmaceutical industry. Analytical review and forecast of the pharmaceutical market development.
Registration is open on the website www.arfp.ru
“AKRIKHIN” is one of the leading Russian pharmaceutical companies producing effective, affordable and high-quality medicines for the therapeutic groups most demanded by Russian patients. The company’s product portfolio includes about 200 drugs, more than 55% of which are sold are included in the VED list. The drugs belong to the main pharmacotherapeutic areas: pulmonology, endocrinology, dermatology, cardiology, neurology, gynecology, etc. and are produced in full compliance with GMP standards. Fully complying with the state and industry priorities, AKRIKHIN JSC actively participates in the localization and import substitution of medicines both by its own Research and Development Center and in partnership with international pharmaceutical manufacturers. The “AKRIKHIN” company employs 1,500 employees, of which more than 800 are at the production site in Staraya Kupavna, Moscow region.
PHARMASYNTEZ is a leading domestic manufacturer of medicines for the treatment of socially significant diseases such as tuberculosis, HIV, oncology, diabetes mellitus, and hepatitis. Production facilities are represented by five modern high-tech factories in the cities: Ussuriysk, Irkutsk, Bratsk, Tyumen, St. Petersburg. The company’s product portfolio includes over 170 types of drugs in various dosage forms: capsules, tablets, granules, infusion solutions, dry sterile powders and lyophilisates, as well as solutions for injections. More than 80% of manufactured drugs are included in the list of vital and essential drugs. The annual production volume exceeds 70 million packages. Revenue at the end of 2019 amounted to 22.7 billion rubles.
Long Sheng Pharma is a structural division of the Chinese State Holding for the production and trade of chemical and pharmaceutical equipment, pharmaceutical raw materials and petrochemical products. Today Long Sheng Pharma has three international offices (Hong Kong, Beijing, Moscow), dozens of highly qualified employees, about 200 business partners in more than 40 countries. Over 20 years in the pharmaceutical industry, Long Sheng Pharma has gained a reputation as a reliable international business partner, a leading supplier to the CIS and Eastern Europe.
General information partner — Pharmaceutical Bulletin
Media partners: Duma TV channel, Komsomolskaya Pravda publishing house, Regions of Russia media holding, Remedium.ru information and analytical portal, GMP News Media project, Moskovskiye Apteki (Moscow Pharmacies) newspaper for pharmacy specialists, social network for professionals of the pharmaceutical industry "Pharma RF", information and analytical journal "Pharmacy Union", the scientific journal "Development and registration of medicines", the journal "Pharmaceutical technologies and packaging".
Conference partners: